MRK - Merck & Co., Inc.
85.04 0.00 (0.00%)
After hours: 4:57PM EDT
| Previous close | 84.69 |
| Open | 84.90 |
| Bid | 84.55 x 1400 |
| Ask | 85.12 x 1200 |
| Day's range | 84.59 - 85.10 |
| 52-week range | 66.10 - 87.35 |
| Volume | 4,734,356 |
| Avg. volume | 8,386,546 |
| Market cap | 217.734B |
| Beta (3Y monthly) | 0.32 |
| PE ratio (TTM) | 23.85 |
| EPS (TTM) | 3.57 |
| Earnings date | 29 Oct 2019 |
| Forward dividend & yield | 2.20 (2.60%) |
| Ex-dividend date | 2019-09-13 |
| 1y target est | 96.36 |
- Zacks
J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View
J&J (JNJ) comes up with encouraging third-quarter 2019 results.
- Zacks
Why Merck (MRK) is Poised to Beat Earnings Estimates Again
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks
Seattle Genetics Up More Than 20% in 3 Months: Here's Why
Seattle Genetics' (SGEN) only marketed product, Adcetris, has been performing well since its launch. The company's established pipeline candidates are also progressing well.
- Yahoo Finance
Merck CEO: Stepping down from Trump council was 'not a political issue'
Kenneth Frazier, the CEO of pharmaceutical giant Merck, explains in a new interview why he decided to publicly resign from one of President Trump’s councils in the summer of 2017.
- Yahoo Finance
Pharma industry is 'right in the crosshairs,' Merck CEO Kenneth Frazier says
“Every person running for president has a plan to reduce pharmaceutical pricing,” Merck CEO Kenneth Frazier says. “Some of them I think are legitimate plans, some of them will hurt innovation, which we don’t want.”
- Zacks
Top Ranked Growth Stocks to Buy for October 10th
Top Ranked Growth Stocks to Buy for October 10th
- Zacks
4 Stocks From Highest Job-Creating Sectors in September
Apart from the decent number of new jobs, the unemployment rate in the United States dropped 0.2 percentage points to hit a five-decade low of 3.5% last month.
- Zacks
J&J Ordered by Philadelphia Jury to Pay $8B in Risperdal Case
Philadelphia jury orders J&J (JNJ) to pay punitive damages of $8 billion to a man who claims that the use of Risperdal caused him to develop breasts.
- Zacks
Merck (MRK) Stock Moves -1.33%: What You Should Know
Merck (MRK) closed the most recent trading day at $83.27, moving -1.33% from the previous trading session.
- Yahoo Finance
Merck CEO Ken Frazier set to open Yahoo Finance's All Markets Summit
On Thursday, Kenneth Frazier, the CEO of pharmaceutical giant Merck (MRK), will kick off Yahoo Finance’s annual All Markets Summit in a keynote conversation
- Zacks
Verastem's (VSTM) Copiktra Gets Orphan Drug Designation
Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.
- Business Wire
Merck Issues 2018/2019 Corporate Responsibility Report
Merck (MRK), known as MSD outside the United States and Canada, today issued its 2018/2019 Corporate Responsibility Report. The report highlights the company’s performance and progress in its four corporate responsibility priority areas of Access to Health, Employees, Environmental Sustainability and Ethics & Values. “Operating responsibly is at the heart of our ability to deliver sustainable impact and long-term value for our business and society,” said Kenneth C. Frazier, Merck chairman and chief executive officer.
- Zacks
The Zacks Analyst Blog Highlights: General Dynamics, Merck, Progressive, ServiceNow, and Emerson
The Zacks Analyst Blog Highlights: General Dynamics, Merck, Progressive, ServiceNow, and Emerson
- Zacks
Top Analyst Reports for General Dynamics, Merck & Progressive
Top Analyst Reports for General Dynamics, Merck & Progressive
- Zacks
The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck
The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck
- Zacks
Novo Nordisk Focuses on Pipeline Development Amid Competition
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.
- Zacks
Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY
J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.
- Zacks
Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion
Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.
- Zacks
Merck's Pediatric Filings for Dificid Get FDA's Priority Review
The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.
- Zacks
Why Merck (MRK) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
- Zacks
AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA
AstraZeneca (AZN) gets CRL from the FDA for PT010, its triple-combo inhaler to treat COPD.
- Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
KEYTRUDA is First Anti-PD-1 Therapy Approved as Monotherapy and in Combination with Chemotherapy in First-Line Setting for NSCLC in China
- Business Wire
FDA Accepts Two Applications for Merck’s DIFICID® (fidaxomicin) to Treat Children Aged Six Months Up to 18 years with Clostridium difficile Infections
Merck (MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for DIFICID® (fidaxomicin) for oral suspension, and a supplemental NDA (sNDA) for a new indication for use of DIFICID tablets and oral suspension for the treatment of Clostridium (also known as Clostridioides) difficile infections (CDI) in children aged six months or older. Both applications have received a priority review classification by the FDA.
- Zacks
Merck Sees Hammer Chart Pattern: Time to Buy?
Merck has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks
Merck (MRK) Stock Moves -0.68%: What You Should Know
Merck (MRK) closed the most recent trading day at $83.61, moving -0.68% from the previous trading session.
